-
Hemophilia Fighter Bioverativ Launches On NASDAQ
Thursday, February 2, 2017 - 4:41pmBioverativ Inc (NASDAQ: BIVVV) — the NASDAQ's brand-new biotech company that’s focused on treatments for hemophilia and other blood disorders — listed this week with $325 million in hand after spinning off from Biogen Inc (NASDAQ: BIIB). The company markets treatments such as...
Read More >>